- Home
- XERS vs PNTG Comparison
XERS vs PNTG Comparison
Compare XERS & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | PNTG |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 965.6M | 1.0B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XERS | PNTG |
|---|---|---|
| Price | $5.47 | $32.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $10.43 | ★ $36.83 |
| AVG Volume (30 Days) | ★ 2.1M | 282.2K |
| Earning Date | 05-18-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 20.00 |
| EPS | N/A | ★ 0.84 |
| Revenue | $49,590,000.00 | ★ $947,705,000.00 |
| Revenue This Year | $28.65 | $24.93 |
| Revenue Next Year | $18.33 | $7.52 |
| P/E Ratio | ★ N/A | $40.60 |
| Revenue Growth | ★ 142.67 | 36.31 |
| 52 Week Low | $3.81 | $21.74 |
| 52 Week High | $10.08 | $35.25 |
Technical Indicators
Market Signals| Indicator | XERS | PNTG |
|---|---|---|
| Relative Strength Index (RSI) | 26.31 | 51.94 |
| Support Level | $4.30 | $27.34 |
| Resistance Level | $5.49 | $35.00 |
| Average True Range (ATR) | 0.34 | 1.76 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 3.62 | 62.41 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.